STOCK TITAN

Genetic Technologies - GENE STOCK NEWS

Welcome to our dedicated page for Genetic Technologies news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies stock.

Overview of Genetic Technologies (GENE)

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is a diversified molecular diagnostics company at the forefront of predictive genomics. The company specializes in developing and commercializing advanced genetic testing solutions that integrate DNA-based insights to optimize health outcomes. Operating globally, Genetic Technologies focuses on personalized predictive testing for health, wellness, and serious diseases, with a strong emphasis on oncology, cardiovascular, and metabolic conditions.

Core Business Model

Genetic Technologies operates through a dual revenue model, offering its products and services to both healthcare providers and direct-to-consumer (DTC) markets. Its flagship platform, geneType, provides multi-risk assessment tests that combine genetic and clinical data to deliver actionable insights. The company also markets its EasyDNA brand, which offers a range of genetic tests, including paternity and wellness testing, with significant recurring revenue streams globally. By integrating its proprietary risk stratification platform into healthcare systems, Genetic Technologies enables physicians and individuals to adopt a more preventive approach to disease management.

Product Portfolio and Differentiation

Genetic Technologies' product portfolio includes over 50 risk assessment tests across 14 categories, supported by 25 granted patents and nine pending patents. Its proprietary polygenic risk assessment technology sets it apart in the competitive landscape. Unlike traditional genetic testing, which focuses solely on hereditary factors, the company's solutions incorporate polygenic risk scores to evaluate a broader range of genetic and clinical risk factors. This innovation allows for more comprehensive and personalized risk predictions, particularly in oncology and cardiometabolic diseases.

Market Context and Competitive Landscape

The company operates in the rapidly expanding predictive genomics market, projected to grow at a compound annual growth rate (CAGR) of over 17% and reach $4.6 billion by 2025. Key competitors include established players like 23andMe and Myriad Genetics, as well as emerging startups in the genomics space. Genetic Technologies differentiates itself through its focus on polygenic-integrated risk assessment and its strategic partnerships, such as the collaboration with CancerIQ. This partnership enhances the company's visibility within U.S. healthcare systems and streamlines the integration of its tests into clinical workflows.

Global Reach and Strategic Initiatives

With operations spanning the Asia-Pacific, the United States, and other global markets, Genetic Technologies is committed to scaling its presence. The company employs a capital-light model, leveraging contract-based sales teams to optimize operational efficiency. Its recent initiatives include expanding direct-to-consumer testing programs and integrating its geneType platform into healthcare systems through partnerships. These strategies aim to make its advanced testing solutions more accessible to both clinicians and consumers.

Significance in the Genomics Industry

Genetic Technologies plays a pivotal role in advancing preventive healthcare through genomics. By offering tools that enable early disease risk detection, the company aligns with the broader healthcare industry's shift toward personalized medicine. Its innovative approach to integrating genetic and clinical risk factors positions it as a leader in the field of predictive genomics, contributing to improved health outcomes on a global scale.

Rhea-AI Summary
Genetic Technologies (GTG) has recently announced transformative initiatives, including a partnership with Gold Coast Private Hospital for a 50-patient pilot study, a world-first risk assessment test for Melanoma, and a groundbreaking partnership with the University of Melbourne. These initiatives mark a significant leap forward in precision medicine and early disease detection, positioning geneType at the forefront of transforming DNA testing into a cost-effective, efficient tool for personalized cancer risk management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.45%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited (GTG) announces a share consolidation of its ordinary shares and a change of ratio in its American Depositary Share program. The Effective Date is expected to be December 14, 2023. The Shares will continue to be traded on the ASX under the symbol “GTGDA”, from 14 December to 22 December 2023, before reverting to the symbol “GTG” from 27 December 2023. The ADSs will continue to be traded on The Nasdaq Stock Exchange under the symbol “GENE”.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE) provides an update on its activities for the quarter ending September 30, 2023. Highlights include a partnership with Gold Coast Private Hospital, geneType Multi-Test approval for Pancreatic Cancer, Melanoma, and Atrial Fibrillation in Australia, and being named the sole industry partner for a Medical Research Future Fund (MRFF) grant. Receipts from customers were A$2.0 million, and a peer-reviewed research paper validated geneType's Pancreatic Cancer risk test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
partnership clinical trial
Rhea-AI Summary
Genetic Technologies announces validation of Pancreatic Cancer risk assessment test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
none
-
Rhea-AI Summary
RedChip Companies to air interviews with Knightscope, Soligenix, and Genetic Technologies on Bloomberg TV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited announces partnership with Gold Coast Private Hospital to establish a Precision Medicine Clinic. Positive outcomes could lead to more clinics throughout Healthscope network.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Aridis Pharmaceuticals, Genetic Technologies Limited, and American Resources Corporation on The RedChip Money Report®, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
Genetic Technologies expands geneType Multi-Risk Test in Australia, offering assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited receives grant for CASSOWARY Trial to assess multi-cancer genetic risk assessment in general practice. Results expected to change risk assessment and improve care. GTG to receive funding for test kits and analysis. Trial to recruit 600 participants from eight general practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (GENE) and 60 Degrees Pharmaceuticals (SXTP) on The RedChip Money Report, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none

FAQ

What is the current stock price of Genetic Technologies (GENE)?

The current stock price of Genetic Technologies (GENE) is $0.765 as of February 7, 2025.

What is the market cap of Genetic Technologies (GENE)?

The market cap of Genetic Technologies (GENE) is approximately 3.7M.

What does Genetic Technologies (GENE) specialize in?

Genetic Technologies specializes in predictive genomics, offering genetic testing solutions for health, wellness, and serious diseases like oncology and cardiovascular conditions.

How does Genetic Technologies generate revenue?

The company operates a dual revenue model, targeting healthcare providers through B2B partnerships and direct-to-consumer markets with its EasyDNA and geneType platforms.

What makes Genetic Technologies' products unique?

Its proprietary polygenic risk assessment technology integrates genetic and clinical data, providing more comprehensive and personalized disease risk predictions compared to traditional genetic tests.

Who are Genetic Technologies' competitors?

Competitors include companies like 23andMe and Myriad Genetics, as well as other emerging players in the predictive genomics and molecular diagnostics sectors.

What markets does Genetic Technologies operate in?

The company has a global presence, with operations in the Asia-Pacific, the United States, and other international markets.

What is the geneType platform?

geneType is Genetic Technologies' flagship multi-risk assessment platform that combines genetic and clinical data to deliver actionable health insights.

What is the significance of Genetic Technologies' partnership with CancerIQ?

The partnership integrates geneType into U.S. healthcare systems, streamlining test ordering and enhancing access to polygenic risk assessment for clinicians and patients.

What challenges does Genetic Technologies face?

Challenges include scaling operations, navigating regulatory landscapes, and educating markets about the benefits of its advanced genetic testing solutions.

What is the focus of Genetic Technologies' EasyDNA brand?

EasyDNA specializes in paternity and wellness genetic tests, generating significant recurring revenue across global markets.

How does Genetic Technologies contribute to healthcare innovation?

By advancing polygenic risk assessment and integrating genetic testing into clinical workflows, the company supports the shift toward preventive and personalized medicine.
Genetic Technologies

Nasdaq:GENE

GENE Rankings

GENE Stock Data

3.71M
4.85M
1.87%
0.53%
Diagnostics & Research
Healthcare
Link
Australia
Prahran